At the news
? BULLISHIMPACT 6/10 8-K filed Sep 14, 2026 at 07:15 ET
Immunocore announced it has achieved target enrollment of 540 patients in its Phase 3 TEBE-AM registrational trial evaluating tebentafusp (KIMMTRAK) in previously treated advanced melanoma. Topline overall survival data is expected as early as end of 2026. This is a positive clinical milestone that de-risks the trial timeline but provides no efficacy data yet.
- Target enrollment of 540 patients achieved in Phase 3 TEBE-AM trial of tebentafusp in previously treated advanced melanoma
- Topline overall survival data expected as early as end of 2026
- Trial evaluates tebentafusp as monotherapy and in combination with pembrolizumab vs investigator's choice
- Primary endpoint is overall survival
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access